Impact BioMedical, Inc. (IBO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has a cash flow conversion efficiency ratio of 0.225x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($-8.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Impact BioMedical, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Impact BioMedical, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IBO total debt and obligations for a breakdown of total debt and financial obligations.
Impact BioMedical, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impact BioMedical, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haranga Resources Ltd
AU:HAR
|
-0.202x |
|
Demire Deutsche Mittelstand Real Estate AG
F:DMRE
|
0.053x |
|
Auric Mining Ltd
AU:AWJ
|
0.143x |
|
Korea Refract
KO:010040
|
-0.125x |
|
Baltic Sea Properties AS
OL:BALT
|
0.027x |
|
Panorama Sentrawisata Tbk
JK:PANR
|
0.015x |
|
European Metals Holdings Ltd
AU:EMH
|
0.000x |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Impact BioMedical, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Impact BioMedical, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.24 Million | $-5.64 Million | -0.779x | -671.98% |
| 2023-12-31 | $28.26 Million | $-2.85 Million | -0.101x | +23.95% |
| 2022-12-31 | $32.67 Million | $-4.33 Million | -0.133x | +87.98% |
| 2021-12-31 | $2.94 Million | $-3.25 Million | -1.104x | -610.22% |
| 2020-12-31 | $-5.28K | $-1.14K | 0.216x | +116.83% |
| 2019-12-31 | $94.89K | $-121.98K | -1.286x | -251.97% |
| 2018-12-31 | $197.12K | $-71.99K | -0.365x | +66.34% |
| 2017-12-31 | $295.22K | $-320.34K | -1.085x | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more